JEADV: 1-year effect study of Guselkumab in the treatment of psoriasis

Psoriasis is a chronic systemic inflammatory disease that requires lifelong treatment for many patients to control the disease and its associated complicatio.

Guselkumab is a fully human monoclonal antibody that binds to the p19 subunit of interleuk.

Persistent is a non-interventional study investigating the long-term efficacy, safety and HRQOL of Guselkumab and Ustekinumab in routine clinical practice in patients with moderate to severe psorias.

method

Guselkumab was administered to patients (≥18 years of age) according to clinical practi.

result

Overall, 303 patients were enrolled and treated with Guselkum.

Conclusions: In conclusion, PERSIST is a large, authentic study that provides important evidence for the efficacy and safety of guselkumab outside of randomized controlled tria.

Source: Gerdes S, Asadullah K, Hoffmann M, Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkum.